MedWatch

Lundbeck initiates trial with Genmab's antibody

For the third time this year, Danish Lundbeck takes a Parkinson's candidate to the clinic. The drug is the result of eight years of collaboration with Genmab and it is Lundbeck's first potential antibody therapy.

For the first time ever, Danish drug group Lundbeck takes an antibody-based therapy to the clinic.

The candidate Lu AF82422 stems from an old collaboration deal with Danish biotech company Genmab, and it is the third Parkinson's drug from Lundbeck to reach the clinic in 2018.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier